July 1, 2022
Clover Announces Executive Leadership Appointments
SHANGHAI, China, July 01, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing…
Pharmaceuticals, Biotechnology and Life Sciences
SHANGHAI, China, July 01, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing…
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of…
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile–Mean reduction from baseline in urticaria activity (UAS7)…
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery…
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 30, 2022 (GLOBE…
— Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT — DUBLIN,…
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the…
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and…
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics…
Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax convertible bonds have been…